Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Glycyrrhizic acid nanoparticles inhibit LPS-induced inflammatory mediators in 264.7 mouse macrophages compared with unprocessed glycyrrhizic acid

Authors Wang Wei, Luo M, Fu Y, Wang S, Efferth T, Zu Y

Received 5 September 2012

Accepted for publication 13 November 2012

Published 12 April 2013 Volume 2013:8(1) Pages 1377—1383


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Wei Wang,1–3 Meng Luo,1–3 Yujie Fu,1–3 Song Wang,1–3 Thomas Efferth,4 Yuangang Zu1–3

1Key Laboratory of Forest Plant Ecology, 2Engineering Research Center of Forest Bio-Preparation, 3State Engineering Laboratory of Bio-Resource Eco-Utilization, Northeast Forestry University, Harbin, China; 4Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany

Abstract: Glycyrrhizic acid (GA), the main component of radix glycyrrhizae, has a variety of pharmacological activities. In the present study, suspensions of GA nanoparticles with the average particle size about 200nm were prepared by a supercritical antisolvent (SAS) process. Comparative studies were undertaken using lipopolysaccardide(LPS)-stimulated mouse macrophages RAW 264.7 as in vitro inflammatory model. Several important inflammation mediators such as NO, PGE2, TNF-α and IL-6 were examined. These markers were highly stimulated by LPS and were inhibited both by nano-GA and unprocessed GA in a dose-dependent manner, especially PGE2 and TNF-α. However nano-GA and unprocessed GA inhibited NO only at a high concentration. In general, we found that GA nanoparticle suspensions exhibited much better anti-inflammatory activities compared to unprocessed GA.

Keywords: glycyrrhizic acid, nanoparticle, mouse macrophages RAW 264.7, inflammatory cytokines

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010